News

BD&J Welcomes Dana Alden Fox to Enhance Legal Expertise

BD&J Welcomes Dana Alden Fox to Enhance Legal Expertise

BD&J Expands Legal Team with Experienced Trial Lawyer

Dana Alden Fox, a renowned trial attorney with a prestigious history at Lewis Brisbois, has made a significant career move to join BD&J as a partner. With an impressive 40 years of high-profile trial experience, Fox will play a key role in enriching BD&J's plaintiff practice and navigating complex litigation cases.

Fox's Expertise and Background

Fox is recognized as a top defense trial lawyer in California, and his transition to the plaintiff side emphasizes BD&J's commitment to providing exceptional legal services. In his previous role, he co-chaired the General Liability practice and participated in Civil Rights and Police Litigation Defense Task Forces. This experience positions him well to offer insider insight while defending the rights of plaintiffs.

A Notable Career in Legal Defense

During his tenure at Lewis Brisbois, Fox handled a remarkable variety of high-profile and complex cases, including advising Live Nation in litigation related to the Las Vegas mass shooting and serving as lead counsel in the infamous Los Angeles Dodgers stadium assault case in 2011. His track record extends to defending a movie production company against litigation resulting from an accidental shooting involving Alec Baldwin.

Strategic Transition to Plaintiff Advocacy

In his own words, Dana Alden Fox expressed, "After four decades on the defense side, I've developed a clear understanding of how insurers assess risk and prepare for trial. Joining BD&J allows me to put that experience to work for injured clients and to approach cases with a strategic perspective informed by precisely how the other side operates." This sentiment clearly demonstrates his dedication to advocating for those who have been harmed.

Educational Background and Recognition

Fox earned his Juris Doctor degree with distinction from the McGeorge School of Law at the University of the Pacific and holds a Bachelor of Arts from California State University, Los Angeles. Additionally, Fox is a Fellow of the American College of Trial Lawyers and an Advocate with the American Board of Trial Advocates, highlighting his esteemed qualifications in the legal community.

Growth at BD&J and Future Prospects

BD&J has seen rapid growth over recent years, achieving over $2 billion in recoveries for its clients. The firm continues to expand its team of more than 60 attorneys, positioning itself as a powerful competitor in the personal injury law sector. With Fox's joining, BD&J anticipates enhancing its effectiveness in securing positive outcomes for clients navigating the complexities of legal battles.

About BD&J, PC: BD&J, PC, has proudly served clients across California for over 20 years, dealing in various aspects of personal injury law. Their dedicated attorneys address cases involving motorcycle accidents, pedestrian collisions, premises liability, and more. With a commitment to protecting individual rights, BD&J is thrilled to add Dana Alden Fox to its accomplished team.

Frequently Asked Questions

Who is Dana Alden Fox?

Dana Alden Fox is an esteemed trial lawyer with over 40 years of experience, previously a partner at Lewis Brisbois, and now a partner at BD&J.

What will Fox's role be at BD&J?

Fox will focus on enhancing BD&J's plaintiff practice, applying his extensive defense experience to advocate for injured clients.

What is Fox known for in his legal career?

Fox is known for handling complex and high-profile cases such as the Los Angeles Dodgers stadium assault and advising on the Live Nation litigation.

How has BD&J performed in recent years?

BD&J has expanded rapidly, achieving more than $2 billion in recoveries for clients, showcasing its effectiveness in personal injury law.

What areas of law does BD&J practice?

BD&J specializes in various personal injury areas, including auto accidents, motorcycle collisions, and premises liability cases.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 236

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 294

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 637

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 296

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 281

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 385

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 254

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
"blog__more"> More News Articles